Evidence map›Paper›PMID 38890027›Full record

ArticleTrends in molecular medicine2024

Insights from HIV-1 vaccine and passive immunization efficacy trials.

Shamim Ahmed, Alon Herschhorn

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Trends in molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Highly efficient production of HIV-1Journal of virology · 2025
    Article
  3. Article
  4. Incompletely closed HIV-1Npj viruses · 2025
    Article
  5. mRNA-based HIV-1 vaccines.Clinical microbiology reviews · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Shamim AhmedDivision of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.
Alon HerschhornDivision of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA; Institute for Molecular Virology, University of Minnesota, Minneapolis, MN 55455, USA; Center for Genome Engineering, Medical School, University of Minnesota, Minneapolis, MN 55455, USA; Institute for Engineering in Medicine, University of Minnesota, Minneapolis, MN 55455, USA; Microbiology, Immunology, and Cancer Biology Graduate Program, University of Minnesota, Minneapolis, MN 55455, USA; College of Veterinary Medicine Graduate Program, University of Minnesota, Minneapolis, MN 55455, USA; Molecular Pharmacology and Therapeutics Graduate Program, University of Minnesota, Minneapolis, MN 55455, USA. Electronic address: aherschh@umn.edu.

Funding

Dissecting the mechanisms of HIV resistance in vivo to broadly neutralizing antibodiesU01AI169587 · NIAID · UNIVERSITY OF MINNESOTA · PI Priyamvada Acharya, Brandon James DeKosky · 2022 to 2026
$7.8M
Dissecting the Conformational Flexibility of HIV-1 Envelope GlycoproteinsR01AI167653 · NIAID · UNIVERSITY OF MINNESOTA · PI HERSCHHORN, ALON · 2022 to 2025
$2.9M
NIAID NIH HHS R01 AI167653NIAID NIH HHS U01 AI169587
6 · The paper itself

Abstract

An effective HIV-1 vaccine is still not available, and most vaccine efficacy trials conducted over the years resulted in no significant overall protection. Here we highlight several insights gained from these trials as well as emerging questions that may be important for further guidance to advance current research directions.

Indexed as

AIDS VaccinesHIV-1HIV InfectionsImmunization, PassiveClinical Trials as TopicHIV AntibodiesHumansVaccine EfficacyAIDS VaccinesHIV Antibodiesantibody-mediated cell cytotoxicityantibody-mediated protectionbroadly neutralizing antibodiesHIV-1 vaccinesvaccine efficacy trials

Identifiers

PMID38890027
PMCPMC11466684

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.